COVID-19 and Heart: From Clinical Features to Pharmacological Implications

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jun 26

PMID 32580344

Citations 26

Authors

Vincenzo Russo

Roberta Bottino

Andreina Carbone

Anna Rago

Andrea Antonio Papa

Paolo Golino

Gerardo Nigro

Affiliations

Soon will be listed here.

Abstract

A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.

Citing Articles

Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown.

Russo V, Rapacciuolo A, Pafundi P, de Divitiis M, Volpicelli M, Ruocco A Eur Heart J Digit Health. 2023; 2(1):171-174.

PMID: 37155653 PMC: 7928967. DOI: 10.1093/ehjdh/ztaa018.

Case Report: Spontaneous Left Inferior Epigastric Artery Injury in a COVID-19 Female Patient Undergoing Anticoagulation Therapy.

Abrashev H, Ananiev J, Georgieva E J Clin Med. 2023; 12(5).

PMID: 36902629 PMC: 10003174. DOI: 10.3390/jcm12051842.

The Impact of COVID-19 Pandemic on Hospitalization and Interventional Procedures for Cardiovascular Diseases during the First Wave in Italy.

Russo V, Cante L, Imbalzano E, Di Micco P, Bottino R, Carbone A Int J Environ Res Public Health. 2023; 20(1).

PMID: 36612794 PMC: 9819536. DOI: 10.3390/ijerph20010472.

Formation and activity of NLRP3 inflammasome and histopathological changes in the lung of corpses with COVID-19.

Gholaminejhad M, Forouzesh M, Ebrahimi B, Mahdavi S, Mirtorabi S, Liaghat A J Mol Histol. 2022; 53(6):883-890.

PMID: 36100803 PMC: 9470508. DOI: 10.1007/s10735-022-10101-w.

Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease.

Khan M, Aqtash O, Harris D, Costea A, Gerson M Case Rep Cardiol. 2022; 2022:1157728.

PMID: 36032053 PMC: 9410984. DOI: 10.1155/2022/1157728.

References

Chow J, Alhussaini A, Calvillo-Arguelles O, Billia F, Luk A . Cardiovascular Collapse in COVID-19 Infection: The Role of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO). CJC Open. 2020; 2(4):273-277. PMC: 7194983. DOI: 10.1016/j.cjco.2020.04.003. View

White N, Pukrittayakamee S, Hien T, Faiz M, Mokuolu O, Dondorp A . Malaria. Lancet. 2013; 383(9918):723-35. DOI: 10.1016/S0140-6736(13)60024-0. View

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

Mehra M, Desai S, Ruschitzka F, Patel A . RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; . PMC: 7255293. DOI: 10.1016/S0140-6736(20)31180-6. View

Costedoat-Chalumeau N, Hulot J, Amoura Z, Leroux G, Lechat P, Funck-Brentano C . Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford). 2007; 46(5):808-10. DOI: 10.1093/rheumatology/kel402. View

Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View

. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3):185-188. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009. View

Danilczyk U, Sarao R, Remy C, Benabbas C, Stange G, Richter A . Essential role for collectrin in renal amino acid transport. Nature. 2006; 444(7122):1088-91. DOI: 10.1038/nature05475. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

10.

Genovese M, Rubbert-Roth A, Smolen J, Kremer J, Khraishi M, Gomez-Reino J . Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013; 40(6):768-80. DOI: 10.3899/jrheum.120687. View

11.

Arbustini E, Narula N, Dec G, Reddy K, Greenberg B, Kushwaha S . The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013; 62(22):2046-72. DOI: 10.1016/j.jacc.2013.08.1644. View

12.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Diaz J . Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020; 27(3). PMC: 7184445. DOI: 10.1093/jtm/taaa041. View

15.

Lippi G, Lavie C, Sanchis-Gomar F . Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3):390-391. PMC: 7127395. DOI: 10.1016/j.pcad.2020.03.001. View

16.

Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K . Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381(9877):1541-50. DOI: 10.1016/S0140-6736(13)60250-0. View

17.

Acharya D, Robertson P, Neal Kay G, Jackson L, Warnock D, Plumb V . Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012; 35(12):738-40. PMC: 6652687. DOI: 10.1002/clc.22047. View

18.

Chen C, Yan J, Zhou N, Zhao J, Wang D . [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48(7):567-571. DOI: 10.3760/cma.j.cn112148-20200225-00123. View

19.

Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

20.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View